Table 3.
Univariate and multivariate survival analyses evaluating GLB, ALB, and AGR influencing CSS in HCC of the training cohort.
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Variable | 5-year CCS | Log rank χ2 test | P | HR(95%CI) | P |
| Sex | 0.463 | 0.496 | NI | ||
| Male | 26.5% | ||||
| Female | 29.1% | ||||
| Age | 0.059 | 0.808 | NI | ||
| ≤60 | 26.6% | ||||
| >60 | 27.4% | ||||
| HbsAg | 0.027 | 0.870 | NI | ||
| negative | 28.8% | ||||
| positive | 28.0% | ||||
| ALT (U/L) | 0.873 | 0.350 | NI | ||
| ≤45 | 28.2% | ||||
| >45 | 22.1% | ||||
| AFP (ng/ml) | 7.727 | 0.005 | 0.288 | ||
| ≤13.6 | 36.5% | Reference | |||
| >13.6 | 20.7% | 1.221 (0.845-1.764) | |||
| Cirrhosis | 3.400 | 0.065 | NI | ||
| absent | 30.5% | ||||
| present | 25.9% | ||||
| Vascular invasion | 6.255 | 0.012 | 0.004 | ||
| absent | 27.6% | Reference | |||
| present | 25.1% | 1.847 (1.221-2.795) | |||
| Tumor multiplicity | 11.811 | 0.001 | 0.000 | ||
| solitary | 18.2% | Reference | |||
| multiple | 46.2% | 0.361 (0.230-0.567) | |||
| Tumor size (mm) | 34.515 | 0.000 | 0.000 | ||
| ≤ 5 | 34.7% | Reference | |||
| > 5 | 14.5% | 2.308 (1.588-3.354) | |||
| Edmondson grade | 27.857 | 0.000 | 0.000 | ||
| I-II | 36.6% | Reference | |||
| III-IV | 11.4% | 2.784 (1.694-4.573) | |||
| GLB (g/L) | 10.625 | 0.001 | 0.023 | ||
| ≤ 32.7 | 31.3% | Reference | |||
| > 32.7 | 14.2% | 1.865 (1.089-3.194) | |||
| ALB (g/L) | 10.038 | 0.002 | 0.046 | ||
| ≤ 40.6 | 20.1% | Reference | |||
| > 40.6 | 37.7% | 0.658 (0.436-0.993) | |||
| AGR | 13.172 | 0.000 | 0.358 | ||
| ≤ 1.4 | 20.7% | Reference | |||
| > 1.4 | 39.4% | 0.811 (0.519-1.267) | |||
NI: not included in multivariate survival analysis. HR: hazard ratio, CI: confidence interval, GLB: globulin, ALB: albumin, AGR: albumin/globulin ratio.